Bayer’s Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

 Bayer’s Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

Bayer’s Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

Shots:

  • The approval is based on two P-III studies evaluating the diagnostic results of Gadavist enhanced cardiac MRI to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD
  • Gadobutrol-enhanced cardiac MRI demonstrated efficacy in global clinical studies and provide details about the functions of the heart muscles to support the management of patients with CAD
  • Gadavist is an approved contrast agent in >100 countries including the US, EU, Japan for multiple indications i.e, CE-MRA, CE-MRI of the liver and kidneys, CNS and all body regions

Click here to read full press release/ article | Ref: Bayer | Image: Office Snapshots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post